































TABLE OF CONTENTS   Page DEDICATION................................................................................................................................................ ii ACKNOWLEDGEMENTS......................................................................................................................... iii LIST OF TABLES ........................................................................................................................................ ix LIST OF FIGURES ........................................................................................................................................x LIST OF ABBREVIATIONS ....................................................................................................................xii Chapter I.     INTRODUCTION ................................................................................................................................. 1           Glutamatergic Signaling ............................................................................................................... 1                Fast Glutamatergic Transmission....................................................................................... 2                     GluAs.......................................................................................................................................... 2                     GluNs.......................................................................................................................................... 5                Long‐Term Potentiation and Long‐Term Depression ............................................... 7                Signal Transduction Mechanisms of Plasticity ............................................................. 9           Metabotropic Glutamate Receptors (mGluRs) .................................................................11                Structure and Classification ................................................................................................11                Group I mGluRs ........................................................................................................................12                     Signaling.................................................................................................................................12                     Pharmacology ......................................................................................................................13                     Localization...........................................................................................................................15                Group II mGluRs.......................................................................................................................17                Group III mGluRs .....................................................................................................................17                     Signaling.................................................................................................................................17                     Pharmacology ......................................................................................................................18                     Localization...........................................................................................................................20                Involvement in Plasticity......................................................................................................22                     Group I mGluRs ...................................................................................................................22                     Group II mGluRs..................................................................................................................23                     Group III mGluRs................................................................................................................23                Implications in Behaviors and Disease States.............................................................25                     Group I mGluRs ...................................................................................................................25                     Group II mGluRs..................................................................................................................26                     Group III mGluRs................................................................................................................27           The Bed Nucleus of the Stria Terminalis (BNST) ............................................................28                The Extended Amygdala.......................................................................................................28                Anatomy ......................................................................................................................................29 
  vi 
               Circuitry.......................................................................................................................................30           Drug Addiction ...............................................................................................................................33                Reward Circuitry......................................................................................................................33                Dopamine and Other Biogenic Amines ..........................................................................34                Self‐Administration as an Animal Model of Addiction ............................................35                Glutamatergic Transmission as a Substrate of Drug Exposure ...........................36                     AMPAR/NMDAR ratios ....................................................................................................36                     Drug‐Induced Disruption of ex vivo Plasticity .......................................................39                mGluR5‐LTD in the BNST is Disrupted by Cocaine Exposure..............................41           Stress and Anxiety ........................................................................................................................42                Stress Circuitry .........................................................................................................................43                Compounds Targeting Glutamatergic Signaling are Anxiolytic...........................44                Animal Models of Anxiety ....................................................................................................45                     Types of Behavioral Stressors ......................................................................................45                     Assaying for Anxiety‐Related Behaviors in Rodents ..........................................45                     Genetic Mouse Models .....................................................................................................46                Anxiety Versus Fear................................................................................................................46                     Anatomical Circuit Distinction of Anxiety Versus Fear .....................................47                Adrenergic Signaling ..............................................................................................................48                     AR‐Mediated Behaviors...................................................................................................49                     α1 Adrenergic Receptors (α1 ARs).............................................................................49                α1‐LTD in the BNST................................................................................................................50           Summary...........................................................................................................................................51                Global Hypothesis and Specific Aims, I ..........................................................................51                     Hypothesis.............................................................................................................................51                     Specific Aims ........................................................................................................................51                Global Hypothesis and Specific Aims, II.........................................................................52                     Hypothesis.............................................................................................................................52                     Specific Aims ........................................................................................................................52 II.    MATERIALS AND METHODS......................................................................................................53           Animals..............................................................................................................................................53           Brain Slice Preparation...............................................................................................................53           Field Potential Recordings........................................................................................................54                Drug Application......................................................................................................................55                Single‐Train LTP ......................................................................................................................56           Submerged Chamber Drug Experiments ............................................................................56           Slice Biotinylation.........................................................................................................................57                Biotinylation ..............................................................................................................................57                Pulldown .....................................................................................................................................57           Western Blotting ...........................................................................................................................59                Tissue Punching .......................................................................................................................59                Homogenization .......................................................................................................................59                SDS‐PAGE ....................................................................................................................................60                Western Blots............................................................................................................................60 
  vii 
          Immunohistochemistry (DAB)................................................................................................62           Restraint Stress..............................................................................................................................63                Acute (60‐minute) Restraint Stress.................................................................................63                Chronic Restraint Stress .......................................................................................................64           In Vivo Drug Exposure.................................................................................................................64 III.   MGLUR5, LTD, ERK, AND COCAINE IN THE BNST ...........................................................65           Introduction ....................................................................................................................................65                mGluR5 and Cocaine ..............................................................................................................65                ERK, and its Activation by Cocaine ..................................................................................65           Results ...............................................................................................................................................66                mGluR5‐LTD in the BNST is ERK1‐Dependent...........................................................66                Acute Cocaine Induces ERK Activation in the BNST.................................................72                MPEP Does Not Block Cocaine‐Induced ERK Activation ........................................72                Lack of Gross Changes in Surface mGluR5 After Cocaine.......................................74                DHPG‐Induced Depression in Field Potential Recordings is Not                Disrupted by Cocaine.............................................................................................................75           Discussion ........................................................................................................................................78                ERK Activation in the BNST by mGluR5 and Cocaine ..............................................78                mGluR5 Itself May Not Be Disrupted by Cocaine in the BNST.............................79                Limitations of Westerns With in vivo Changes ...........................................................80                Possibility of Stress‐Induced ERK Activation in IHC................................................81                Limitations of Fractionation, Quantification in Biotinylation Procedure .......82                Homer Proteins, and Their Regulation by Drugs of Abuse....................................83                Limitations of pan‐Homer Antibody ...............................................................................84                DHPG‐Induced Depression in Field Potential Recordings is Not                 a Model For Whole‐Cell mGluR5‐LTD.............................................................................86 IV.   MGLUR8, α1 ARS, AND STRESS IN THE BNST....................................................................88           Introduction ....................................................................................................................................88                Group III mGluRs .....................................................................................................................88                mGluR8, and mGluR8 Knockout Mice.............................................................................88                α1 ARs and Stress/Anxiety..................................................................................................90           Results ...............................................................................................................................................92                Group III Agonist L‐AP4 and mGluR8‐Selective Agonist DCPG Depress                Excitatory Transmission in BNST.....................................................................................92                DCPG and L‐AP4 Effects Not Potentiated by PHCCC, and Absent in                 mGluR8 Knockout Mice.........................................................................................................96                DCPG Acts Presynaptically to Depress Excitatory Transmission in BNST .....97                α1 AR Activation Abolishes mGluR8 Suppression of Transmission..................99                     mGluR8 Function After α1 AR Activation is Partially Recovered                      With a High Concentration of DCPG...........................................................................99                     mGluR8 Activation Does Not Affect Subsequent α1 AR Activation...........101                mGluR8 Modulation of Transmission is Disrupted After Acute  
  viii 






 Figure  Page 1.          Circuit Diagram of the BNST.................................................................................................31 2.          mGluR5‐LTD in the BNST is Disrupted by Cocaine ....................................................67 3.          100 μM DCPG Induces ERK Phosphorylation in BNST Slices.................................68 4.          Total Protein Levels of ERK1, ERK2, or mGluR5 Were Unchanged               After Chronic Cocaine ..............................................................................................................70 5.          Preinjection of MPEP Prior to in vivo Cocaine Rescues               ex vivo mGluR5‐LTD ................................................................................................................71 6.          Cocaine Induces Significant ERK Phosphorylation in the BNST...........................73 7.          MPEP Preinjection Does Not Block Cocaine‐Induced ERK                Phosphorylation in BNST......................................................................................................73 8.          No Gross Change in Surface mGluR5 Levels was Observed After                Chronic Cocaine in BNST or Striatum..............................................................................76 9.          DHPG‐Induced Depression in Field Potential Recordings is Not                Disrupted by Bath‐Applied Cocaine .................................................................................77 10.       Scanned Film of a pan‐Homer Western Blot..................................................................85 11.       Group III Agonists Depress EPSCs in the BNST ............................................................89 12.       Chronic Restraint Stress Disrupts α1‐LTD in the BNST............................................91 13.       mGluR8, Not mGluR4, Mediates the Effects of L‐AP4 in the BNST.......................93 14.       The mGluR8‐Selective Agonist DCPG Depresses Excitatory               Transmission in the dBNST...................................................................................................95 15.       DCPG Inhibits Glutamatergic Transmission in the dBNST ......................................98 16.      Activation of α1 Adrenergic Receptors Disrupts mGluR8 Effects              on Excitatory Transmission. ...............................................................................................100  
  xi 




 α1 Adrenergic Receptor‐Mediated Long‐Term Depression....................................... α1‐LTD  Adenylate Cyclase................................................................................................................................... AC Artificial Cerebrospinal Fluid ....................................................................................................... ACSF Adrenocorticotropic Hormone ...................................................................................................ACTH (S)‐(4‐fluoro‐phenyl)‐{3‐[3‐(4‐fluoro‐phenyl)‐[1,2,4]oxadiazol‐5‐yl]‐ piperidin‐1‐yl}‐methanone ................................................................................................ADX47273 A Kinase Anchoring Protein 79/150 ........................................................................ AKAP79/150 
N,N'‐Bis(diphenylmethyl)‐1,2‐ethanediamine dihydrochloride............................AMN082 α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic Acid Receptor...................... AMPAR Adrenergic Receptor .............................................................................................................................AR (3aS,6aS)‐6a‐naphthalen‐2‐ylmethyl‐5‐methyliden‐hexahydro‐ cyclopental[c]furan‐1‐on................................................................................................ Bay 36‐7620 Basolateral Amygdala ........................................................................................................................ BLA Bed Nucleus of the Stria Terminalis ......................................................................................... BNST Ca2+/Calmodulin‐Dependent Protein Kinase II ................................................................CaMKII cyclic Adenosine Monophosphate ............................................................................................. cAMP Type 1 Endocannabinoid Receptor.............................................................................................CB1R 3‐cyano‐N‐(1,3‐diphenyl‐1H‐pyrazol‐5‐yl)benzamide................................................. CDDPB Central Nucleus of the Amygdala...................................................................................................CeA (R,S)‐2‐Amino‐2‐(2‐chloro‐5‐hydroxyphenyl)acetic acid .............................................. CHPG 7‐hydroxyiminocyclopropan[b]chromen‐1a‐carboxylic acid ethyl ester......... CPCCOEt  
  xiii 
3,3′‐difluorobenzaldazine (DFB), N‐{4‐Chloro‐2‐[(1,3‐dioxo‐1,3‐dihydro‐ 2H‐isoindol‐2‐yl)methyl]phenyl}‐2‐hydroxybenzamide ............................................. CPPHA cAMP‐Responsive Elements............................................................................................................ CRE cAMP‐Responsive Element Binding Protein......................................................................... CREB Corticotropin‐Releasing Factor ......................................................................................................CRF Dopamine ...................................................................................................................................................DA 3,3'‐Diaminobenzidine ......................................................................................................................DAB Diacylglycerol ........................................................................................................................................DAG Dopamine Transporter......................................................................................................................DAT Dopamine‐β‐Hydroxylase ............................................................................................................... DBH Dorsal Subdivision of the Anterior BNST.............................................................................dBNST (S)‐3,4‐Dicarboxyphenylglycine................................................................................................. DCPG  (S)‐3,5‐Dihydroxyphenylglycine...............................................................................................DHPG Endocannabinoid..................................................................................................................................eCB Endocannabinoid‐Mediated Long‐Term Depression..................................................eCB‐LTD Epinephrine.................................................................................................................................................. E Elevated Plus Maze .............................................................................................................................EPM Excitatory Postsynaptic Current ................................................................................................. EPSC Extracellular Signal‐Regulated Kinase/ Mitogen‐Activated Protein Kinase ................................................................................ERK/MAPK Field Excitatory Postsynaptic Potential ..................................................................................fEPSP Fragile X Mental Retardation Protein ......................................................................................FMRP γ‐amino‐butyric Acid ......................................................................................................................GABA Glutamic Acid Decarboxylase .........................................................................................................GAD 
  xiv 
Glutamate Receptor Interacting Proteins 1 and 2........................................................GRIP1/2 Guanosine 5’‐Diphosphate...............................................................................................................GDP G‐Protein‐Coupled Receptor.........................................................................................................GPCR Guanosine 5’‐Triphosphate............................................................................................................. GTP Hypothalamic‐Pituitary‐Adrenal Axis ..............................................................................HPA Axis High‐Frequency Stimulation............................................................................................................HFS Immediate‐Early Gene.........................................................................................................................IEG Ionotropic Glutamate Receptor ...................................................................................................iGluR Intraperitoneal......................................................................................................................................... i.p. 1,4,5‐Triphosphate................................................................................................................................. IP3 3‐4‐Dihydro‐2H‐pyrano[2,3‐b]quinolin‐7‐yl‐(cis‐4‐ methoxycyclohexyl)‐methanone ............................................................................... JNJ16259685 Kainate Receptor..................................................................................................................................KAR Knockout ....................................................................................................................................................KO L‐(+)‐2‐Amino‐4‐phosphonobutyric acid ............................................................................. L‐AP4 Low‐Frequency Stimulation............................................................................................................. LFS Long‐Term Depression...................................................................................................................... LTD Long‐Term Potentiation ....................................................................................................................LTP (2S)‐2‐Amino‐2‐[(1S,2S)‐2‐carboxycycloprop‐1‐yl]‐3‐(xanth‐9‐yl)  propanoic acid.......................................................................................................................... LY341495  (S)‐(+)‐α‐Amino‐4‐carboxy‐2‐methylbenzeneacetic acid ................................... LY367385 (1R,4R,5S,6R)‐4‐amino‐2‐oxabicyclo[3.1.0]hexane‐4,6‐dicarboxylic Acid... LY379268 Metabotropic Glutamate Receptor..........................................................................................mGluR Metabotropic Glutamate Receptor 5‐Mediated Long‐Term  Depression............................................................................................................................mGluR5‐LTD 
  xv 
(5S,10R)‐(+)‐5‐Methyl‐10,11‐dihydro‐5H‐dibenzo[a,d]cyclohepten‐5,10‐ imine maleate ................................................................................................................................ MK‐801 6‐(4‐Methoxyphenyl)‐5‐methyl‐3‐(4‐pyridinyl)‐isoxazolo[4,5‐c] pyridin‐4(5H)‐one hydrochloride ..........................................................................................MMPIP 2‐methyl‐6‐(phenylethynyl)pyridine ......................................................................................MPEP Medial Prefrontal Cortex ...............................................................................................................mPFC  3‐((2‐Methyl‐1,3‐thiazol‐4‐yl)ethynyl)pyridine hydrochloride ..................................MTEP Noradrenaline ..........................................................................................................................................NA Norepinephrine .......................................................................................................................................NE Norepinephrine Transporter..........................................................................................................NET 
N‐methyl‐D‐aspartate Receptor............................................................................................ NMDAR  N‐ethylmaleimide sensitive fusion protein ...............................................................................NSF Nucleus Accumbens.............................................................................................................................NAc Negative Allosteric Modulator ......................................................................................................NAM Periaqueductal Gray ........................................................................................................................... PAG Parkinson’s Disease ............................................................................................................................... PD Prefrontal Cortex ..................................................................................................................................PFC 
N‐Phenyl‐7‐(hydroxyimino)cyclopropa[b]chromen‐1a‐carboxamide ...................PHCCC Phosphotoinositide..................................................................................................................................PI Protein Interacting with C Kinase 1......................................................................................... PICK1 Protein Kinase A................................................................................................................................... PKA Protein Kinase C ................................................................................................................................... PKC Phospholipase C ....................................................................................................................................PLC Phospholipase D................................................................................................................................... PLD 
  xvi 















































































































































































































































































































vlBNST as was observed in the dlBNST (n = 8, 71.1 ± 4.4% of
baseline; Fig. 4 E and F). Stressed mice, however, had a sig-
niﬁcantly attenuated Naspm-induced reduction in EPSCs as
compared with their naive controls (n = 8, 88.3 ± 4.3% of
baseline; P < 0.05; Fig. 4 E and F).
α1-AR LTD Is Disrupted by Chronic Alcohol Exposure. Stress disorders
and alcoholism are highly comorbid (35). Data from human
studies suggest that NE is increased in the central nervous system
(CNS) of alcoholics (36), where it may play a role in the patho-
genesis of alcoholism (35). Additionally, the adrenergic system
remains an attractive target for intervention in alcoholism (11).
Recently, α1-AR signaling has been linked to drinking behavior in
withdrawn-dependent animals (8). Because of these data and our
chronic stress results, we examined the persistence of α1-AR LTD
in the dlBNST and vlBNST in ethanol-exposed mice. Mice
receiving chronic continuous ethanol (CCE) were exposed to 64 h
of continuous ethanol vapor, whereas mice receiving chronic
intermittent ethanol (CIE) were exposed to 4 days of 16 h of
ethanol vapor with 8-h withdrawal periods interspersed. Both the
ethanol-exposed and sham animals were administered i.p. pyr-
azole daily. Animals were killed 4–6 h into the ﬁnal withdrawal
under each condition. Although we examined a shorter time
course following methoxamine application, both conditions
resulted in signiﬁcantly attenuated responses to α1-AR signaling
from sham mice; however, the LTD was not fully occluded by
these treatments (shammice: n=6, 55.5± 6.5% of baseline; CCE
mice: n=7, 81.1± 7.5%of baseline; CIEmice: n=5, 79.1± 6.3%
of baseline; one-way ANOVA, P < 0.05; Fig. 5). We did not
observe a correlation in the degree of depression between the
dlBNST or vlBNST in the ethanol-treated animals.
Discussion
We ﬁnd that α1-AR activation produces LTD of excitatory
transmission in the BNST that involves CP-AMPARs. Despite the
fact that both α1-AR and mGluR5 are Gq-linked and can elicit
LTD on overlapping neuronal populations in the BNST, we ﬁnd
that these two forms of LTD have distinct maintenance mecha-
nisms. These differences are also apparent when examining the
persistence of these LTDs following environmental challenges.
We previously found that cocaine disrupts mGluR5- but not α1-
AR LTD (13, 14, 19). Here, we report that a chronic stressor
disrupts α1-AR LTD and CP-AMPAR transmission but not
mGluR5 LTD. Moreover, we report that α1-AR LTD is dimin-
ished by chronic ethanol exposure. Finally, our studies uncover an
additional acute enhancement of glutamatergic transmission in
the BNST by α1-ARs, which, as with dopamine actions in the
region, occurs through a CRFR1-dependent process.
α1-AR LTD Is Maintained by a Different Postsynaptic Mechanism Than
mGluR5 LTD in the BNST. Previously, we found that α1-AR LTD
induction occluded the further induction of mGluR5 LTD in the
BNST(19), leadingus tohypothesize thatbothLTDs involved similar
mechanisms (18). Recently, we found that mGluR5 LTD in the
BNST is maintained via postsynaptic mechanisms involving endocy-
tosis and rearrangement of the actin cytoskeleton (14).Wenow show
that α1-AR LTD also requires clathrin-dependent endocytosis.
Unlike mGluR5 LTD, however, a difference in the required time
course of agonist application and a lack of MEK1/2 involvement
suggest that different mechanisms underlie both LTDs. Here, we
present data suggesting that in contrast to mGluR5 LTD, the
AMPARs targeted in α1-AR LTD are CP-AMPARs. Additionally,
themEPSC and sEPSCproﬁles are different betweenmGluR5LTD
and α1-AR LTD. In mGluR5 LTD, a decrease in the frequency of
events is observed with mEPSCs (14), whereas in α1-AR LTD, a
decrease in the amplitude of events is observed with sEPSCs but not
with mEPSCs. The lack of anα1-AR agonist effect on the amplitude
or frequency of mEPSCs suggests thatα1-AR LTD is dependent on
Fig. 4. Chronic restraint stress occludesα1-AR LTDbut notmGluR5 LTD. The 10-
day restraint stress paradigmblockedα1-AR LTD in thevlBNST (n=6;P> 0.78) (A)
and signiﬁcantly attenuatedα1-ARLTD in thedlBNST (B) (n=5 inboth conditions;
P< 0.05). methox,methoxamine. (C andD) Stress exposure does notmanipulate
mGluR5 LTD induced by 100 μM (RS)-3,5-dihydroxyphenylglycine (DHPG) in
either thedlBNST (n=5forbothconditions)or vlBNST(stress:n=7,naive:n=6). (E
and F) Stress paradigm signiﬁcantly attenuated the function of CP-AMPARs in
the vlBNST (min 25–30; n = 8 for both conditions; P < 0.05). n.s., not signiﬁcant.
Fig. 5. Chronic exposure to ethanol attenuates α1-AR LTD in the BNST. (A)
Sham mice demonstrated robust LTD when stimulated with 100 μM
methoxamine (methox), similar to naive mice (n = 6). (B) Response to 100 μM
methoxamine (methox) was attenuated in the BNST in mice that had expe-
rienced onewithdrawal following CCE (n = 7). (C) Methoxamine (methox; 100
μM) resulted in attenuated LTD following a CIE paradigm (n = 5). (D) Histo-
gram comparing sham, CCE, and CIE conditions: both CCE and CIE conditions
are signiﬁcantly attenuated from control conditions by one-way ANOVA (min
40–45; *P < 0.05 for ANOVA; CIE vs. sham, P < 0.05; CCE vs. sham, P < 0.05).
2274 | www.pnas.org/cgi/doi/10.1073/pnas.0905568107 McElligott et al.
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Results  Group III Agonist L‐AP4 and mGluR8‐Selective Agonist DCPG Depress Excitatory Transmission in BNST  Our laboratory has previously reported that the Group III mGluR agonist L‐AP4 depresses excitatory transmission in the BNST (Grueter and Winder, 2005) (Figure 11).  Here, I used field potential recordings and local afferent stimulation in the anterolateral dorsal BNST to further probe the specific Group III mGluR subtypes involved in mediating the effects of L‐AP4 in the dorsal BNST (Figure 13A).  Consistent with our previous finding, a 20‐minute bath application of 200 µM L‐AP4 produced a small yet significant depression of excitatory transmission in BNST‐containing slices (8.8 ± 4.9 peak average percent depression, p < 0.05 versus baseline, paired student’s t‐test; Figure 13C,F).    We observe mGluR8‐like immunoreactivity in the dorsal BNST, suggesting mGluR8 may be mediating L‐AP4 effects in this region (Figure 13B).  To more directly test whether mGluR8 activation has effects on excitatory transmission in the BNST, I utilized the mGluR8‐selective agonist DCPG, which has also been previously shown to depress excitatory transmission in this region (Grueter and Winder, 2005) (Figure 11).  Consistent with this, I found that a 20‐minute application of DCPG depressed excitatory transmission in the BNST as examined by field potential recordings (Figure 14A).  This effect of DCPG was concentration‐dependent, with 10 μM and 30 μM DCPG inducing a depression which did not readily reverse (1 μM: 5.4 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Figure 13. mGluR8, Not mGluR4, Mediates the Effects of L‐AP4 in the BNST. (a) Coronal brain slice showing the dorsal BNST (gray triangle) and the approximate locations of the stimulating and recording electrodes. (b) Confocal image showing a punctate distribution of mGluR8‐like immunoreactivity (red) at the dorsal edge of the rat BNST. A Hoechst counterstain (blue) was used to label cell nuclei. (inset) anatomical schematic with a small box showing the photographed area. Scale bars in 
µm. (c) The Group III agonist L‐AP4 (200 μM) causes a transient yet significant depression in excitatory transmission in BNST (p < 0.05 versus baseline, paired student’s t‐test; n = 6). (inset) representative trace showing the difference in N2 amplitude after L‐AP4 (red trace) compared to baseline (black trace). (d) The mGluR4 potentiator PHCCC (30 μM) does not shift the L‐AP4 effect in WT mice (n = 7). (inset) representative trace showing the difference in N2 amplitude after PHCCC + L‐AP4 (red trace) compared to baseline (black trace). (e) The effect of PHCCC + L‐AP4 is absent in mGluR8 knockout mice (n = 6). (inset) representative traces showing the lack of difference in N2 amplitude after PHCCC + L‐AP4 (red trace) compared to baseline (black trace). (f) No difference in peak effect of average percent depression was observed between PHCCC + L‐AP4 and L‐AP4 alone, and no effect was present in slices from mGluR8 knockout mice (n = 6‐7). Scale bars on traces represent 0.2 mV (y axis) and 2 msec (x axis).
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Figure 14. The mGluR8‐Selective Agonist DCPG Depresses Excitatory Transmission in the dBNST. (a) Representative single experiments demonstrating the effect of 10 μM (closed circles) and 30 μM (open circles) DCPG on excitatory transmission in BNST. (b) DCPG produces a concentration‐dependent depression in excitatory transmission (n = 6‐8). (c) DCPG‐induced depression is unaltered by co‐application of the mGluR4 potentiator PHCCC (n = 5‐8). 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± 2.3, 3 μM: 8.9 ± 2.5, 10 μM: 19.9 ± 4.2, and 30 μM: 16.6 ± 3 peak average percent depression, n = 6‐8; representative single experiments in Figure 14A,B).     DCPG and L‐AP4 Effects Not Potentiated by PHCCC, and Absent in mGluR8 Knockout Mice  To investigate the contribution of mGluR4 to the L‐AP4 effect on excitatory transmission in the BNST, I utilized the mGluR4‐selective allosteric potentiator PHCCC (Maj, et al 2003).  PHCCC was applied 15 minutes prior to a 20‐minute co‐application of L‐AP4 and PHCCC (10.1 ± 2.9 peak average percent depression, Figure 13D,F).  PHCCC failed to shift the peak effect of L‐AP4, suggesting mGluR4 does not contribute to the effects of L‐AP4 on excitatory transmission in this region (L‐AP4: 8.8 ±4.9 peak average percent depression, versus L‐AP4 + PHCCC: 10.1 ± 2.9, peak average percent depression, p > 0.05, student’s t‐test, Figure 13F). To test the role of mGluR8 signaling in the actions of L‐AP4 in the BNST, I repeated the PHCCC + L‐AP4 co‐application experiments using brain slices from mGluR8 knockout mice (Figure 13E,F).  There was no significant effect of L‐AP4 or PHCCC in mGluR8 KO mice (WT: 10.1 ± 2.9 peak average percent depression, versus mGluR8 KO: 2.6 ± 2.8 peak average percent depression, p > 0.05, student’s t‐test; drug effect in KO compared to baseline fails to reach significance with paired student’s t‐test; Figure 13F).  These data suggest mGluR8, and not mGluR4, is the primary mediator of the effects of L‐AP4 on excitatory transmission in the BNST. At higher concentrations, DCPG loses selectivity for mGluR8 and can activate mGluR4 as well (Abitbol, et al 2008; Thomas, et al 2001).  To determine whether 
  97 
mGluR4 was involved in mediating the effect of DCPG in the BNST, I repeated these experiments with the addition of PHCCC.  Adding PHCCC failed to enhance the effect of DCPG, suggesting that mGluR4 is not being recruited by DCPG to regulate excitatory transmission in the BNST (3 µM: 8.9 ± 2.5 peak average percent depression; 3 µM + PHCCC: 8.2 ± 2.8 peak average percent depression, p > 0.05, student’s t‐test, Figure 14C).  The finding that PHCCC does not alter the actions of either DCPG or L‐AP4 in BNST, coupled with the fact that DCPG has affinity for mGluRs 8 and 4, but not 7, suggests that mGluR8 is the primary receptor mediating the effects of Group III agonists on transmission in the BNST.          DCPG Acts Presynaptically to Depress Excitatory Transmission in BNST To test the likely site of action of L‐AP4 and DCPG, paired pulse ratios (PPR) of EPCSs were examined. (PPR data was obtained by Brad Grueter, PhD.)  There was an enhancement of PPR after DCPG application, consistent with group III mGluRs reducing glutamate release probability to depress transmission (1.25 ± 0.14 fold of basal paired‐pulse ratio).  To further confirm a presynaptic localization of mGluR8, spontaneous EPSC (sEPSC) frequency and amplitude were examined prior to and following application of 10 μM DCPG (Figure 15A‐D). (sEPSC data was obtained by Yuval Silberman, PhD.)  In agreement with the PPR data, the mean frequency of sEPSCs was significantly decreased following DCPG application (2.4 ± 0.6 Hz control, versus 1.5 ± 0.5 Hz post‐DCPG, p ≤ 0.01, paired student’s t‐test; Figure 15A,C,D).  The mean amplitude of sEPSCs in the BNST was modestly but significantly decreased by DCPG application (‐8.0 ± 0.5 pA control, versus ‐6.5 ± 0.5 pA post‐DCPG, p ≤ 0.005, 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Figure 15. DCPG Inhibits Glutamatergic Transmission in the dBNST. (a) Representative recordings in the dBNST demonstrating the ability of 10 μM DCPG to inhibit the frequency of sEPSC events. (b) Representative sEPSC traces showing the effect of DCPG on sEPSC amplitude. (c) Mean effect of DCPG on sEPSC frequency (Hz, left Y axis) and amplitude (pA, right Y axis). (frequency: p ≤ 0.01, paired t‐test; 
amplitude: p ≤ 0.005, paired t‐test; n = 8). (d) DCPG reduces sEPSC frequency and amplitude over time, expressed as % control.  Note the larger % inhibition caused by DCPG on sEPSC frequency as compared to sEPSC amplitude. (work done and figure generated by Yuval Silberman, PhD.) 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paired t‐test; Figure 15B,C,D).  DCPG had no effect on sEPSC kinetics (Figure 15B).  As shown in Figure 15D however, the effect on frequency was much more pronounced than that on amplitude.  Taken together, these data suggest that mGluR8 in the BNST functions as a presynaptic autoreceptor, whose activation reduces glutamate release.  α1 AR Activation Abolishes mGluR8 Suppression of Transmission To determine whether α1 AR activation could alter mGluR8 activity, I first took a pharmacological approach by activating both receptors in series.  As previously reported, a 20‐minute application of 100 µM methoxamine, an α1 AR agonist, produced a robust, persistent depression of excitatory transmission consistent with long‐term depression (LTD) (McElligott and Winder, 2008; Figure 17E).  After allowing 60 minutes for the methoxamine effect to be established, DCPG (10 µM) was applied for 20 minutes (Figure 16B).  Consistent with what has been reported for L‐AP4 in the PVN (Gordon and Bains, 2003), the effect of DCPG on excitatory transmission was abolished after methoxamine application when compared to the effect of DCPG alone (control DCPG: 19.9 ± 4.2 peak average percent depression, versus 1.9 ± 2.1 after methoxamine, p ≤ 0.005, Friedman’s non‐parametric repeated measures ANOVA and Dunn’s multiple comparison test; Figure 16A, B and inset).            
mGluR8 Function After α1 AR Activation is Partially Recovered With a High 
Concentration of DCPG To determine whether this lack of an effect of DCPG after methoxamine constituted a shift in potency or efficacy, I repeated the experiment using a high concentration 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Figure 16. Activation of α1 Adrenergic Receptors Disrupts mGluR8 Effects on Excitatory Transmission. (a) The effect of 10 μM DCPG alone (p ≤ 0.001 vs. baseline, 
n = 8). (b) 100 μM methoxamine‐induced depression abolishes the effect of 10 μM DCPG (n = 6). (inset) DCPG‐induced depression of transmission is lost after methoxamine (p ≤ 0.005, Friedman’s non‐parametric repeated measures ANOVA and Dunn’s multiple comparison test, n = 6‐8). (c) A high concentration of DCPG (30 μM) is able to produce a depression after methoxamine, suggesting a shift in DCPG potency (p < 0.05 vs. post‐methoxamine baseline, paired student’s t‐test, n = 7). (d) 10 μM DCPG does not disrupt subsequent methoxamine‐induced depression (n = 5). (inset) 100 μM methoxamine effect is intact after 10 μM DCPG (n = 5‐6). 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of DCPG (30 μM).  The 30 μM concentration of DCPG was able to produce a significant depression after methoxamine, suggesting a shift in the potency of this compound at mGluR8 had occurred (12.5 ± 8.1 peak average percent depression compared to post‐methoxamine baseline, p < 0.05, paired student’s t‐test; Figure 16C and inset).             
mGluR8 Activation Does Not Affect Subsequent α1 AR Activation In contrast, when the order of drug application was reversed and slices were pretreated for 20 minutes with 10 μM DCPG, 100 μM methoxamine still depressed excitatory transmission (control methoxamine: 25.6 ± 6.6 peak average percent depression versus 21.5 ± 4.5 after DCPG, p > 0.05 for control versus after DCPG, student’s t‐test; Fig 16D and inset).             mGluR8 Modulation of Transmission is Disrupted After Acute Restraint Stress Next, I examined whether mGluR8 function is disrupted by acute in vivo stress exposure.  Mice underwent one 60‐minute restraint session and were euthanized immediately afterwards (see Figure 17 schematic).  In slices prepared from these mice, the effect of 10 µM DCPG on excitatory transmission was attenuated compared to pooled interleaved naïve controls (one‐way ANOVA: F(3, 29) = 4.802, p = 0.0078; stressed: 8.6 ± 1.4 peak average percent depression, versus 17.5 ± 2.0 for pooled interleaved naïve controls; p ≤ 0.01, Dunnett’s post hoc comparison, Figure 17A,B).          
α1 AR Function is Modestly Disrupted After Acute Restraint Stress Our laboratory has previously reported that chronic restraint stress disrupts α1 AR‐mediated LTD (α1‐LTD) induction in the BNST (McElligott, et al 2010).  Here I 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Figure 17. A Single Restraint Stress Exposure Disrupts mGluR8 Regulation of Transmission in the BNST. (top) schematic representing the acute restraint stress timeline. (a) 10 μM DCPG‐induced depression (pooled interleaved naïve controls, closed circles) is disrupted in mice that underwent a single restraint stress (open circles) (n = 8‐13). (b) peak average percent depression of 10 μM DCPG in pooled interleaved naïve control mice and acutely restrained mice (p ≤ 0.01, Dunnett’s post hoc comparison; n = 8‐13). (c) Group II agonist LY379268‐induced depression (1 μM) is intact after restraint (open circles) (n = 5‐7). (d) peak average percent depression by 1 μM LY379268 in naïve and restrained mice (n = 5‐7). (e) Methoxamine‐induced depression (100 μM) is altered in acutely restrained mice (open circles) (n = 4‐5). (f) (left panel) Peak average percent depression by methoxamine is modestly but significantly attenuated in naïve versus acutely restrained mice (p < 0.05, student’s t‐test, n = 4‐5). (right panel) Maximal effect of methoxamine is still modestly but significantly attenuated at a late timepoint (45‐52 minutes after drug removal) (p < 0.05, student’s t‐test, n = 4‐5). 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examined the impact of a single restraint stress on this plasticity.  Both the peak and late effects of 100 μM methoxamine were modestly but significantly attenuated after a single restraint stress (peak effect: 18.0 ± 1.7 and 24.4 ± 3.0 peak average percent depression for single restraint versus naïve controls, respectively; p < 0.05,  student’s t‐test; late effect: 10.2 ± 1.4 and 17.9 ± 2.9 average percent depression for single restraint versus naïve controls, respectively; p < 0.05, student’s t‐test; Figure 17E,F).  Taken together with our previous study (McElligott, et al 2010), this suggests α1 ARs in the BNST were likely activated by the single restraint stress.  
Group II mGluR Function is Intact After Acute Restraint Stress  Interestingly, sensitivity to the Group II agonist LY379268 was unaffected after acute stress, demonstrating that the stress‐induced disruption is specific to mGluR8 (stressed: 35.7 ± 7.7 peak average percent depression, versus 32.5 ± 4.7 for interleaved controls; Figure 17C,D).             mGluR8 Function is Disrupted After Chronic Stress Finally, I examined whether mGluR8 function is disrupted by a more chronic stressor.  Using a protocol shown previously to disrupt α1‐LTD in the BNST (McElligott, et al 2010), mice underwent 2 hours of restraint stress for 10 consecutive days, and were euthanized 24 hours after their last session, on day 11 (see Figure 18 schematic).  As with a single in vivo stress, the effect of 10 μM DCPG was significantly attenuated following chronic restraint stress (chronic restraint: 9.9 ± 3.1 peak average percent depression, versus 17.5 ± 2.0 for pooled interleaved naïve controls, p < 0.05, Dunnett’s post hoc comparison; Figure 18 A,B).  I also 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Figure 18. mGluR8 Function Remains Disrupted After Chronic Stress. (top) schematic representing the chronic restraint stress timeline. (a) 10 μM DCPG‐induced depression (pooled interleaved naïve controls, closed circles) is disrupted in mice that underwent chronic restraint stress (open circles) (n = 5‐13). (b) peak average percent depression of 10 μM DCPG in pooled interleaved naïve control mice and chronic restraint mice (p < 0.05, Dunnett’s post hoc comparison, n = 5‐13). (c) DCPG‐induced depression is also attenuated in α2A AR KO mice, a model of chronic stress. (d) peak average percent depression of 10 μM DCPG in pooled interleaved naïve control mice and α2A AR KO mice (p < 0.05, Dunnett’s post hoc comparison, n = 6‐13). 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assessed mGluR8 function in α2A AR knockout mice, which exhibit chronic adrenergic system dysregulation and are considered a chronic stress model (Schramm, et al 2001).  The effect of DCPG was also diminished in these mice as compared to pooled interleaved naïve controls (α2A AR KO: 9.6 ± 2.6 peak average percent depression, versus 17.5 ± 2.0 for pooled interleaved naïve controls, p < 0.05, Dunnett’s post hoc comparison; Figure 18C,D).  Taken together, these data reveal that mGluR8 regulation of excitatory transmission can be overridden by adrenergic signaling in the BNST and specifically disrupted by both acute and chronic in vivo stress.         
Discussion           Group III ligand effects in BNST are mediated by presynaptic mGluR8  mGluRs have been shown to alter glutamatergic transmission, playing key roles in several forms of plasticity throughout the brain.  In contrast to ionotropic glutamate receptors, the slower nature of mGluR signaling allows for potentially more long‐lasting, adaptive changes in synaptic strength.  Within the BNST, agonists to Groups I, II, and III mGluRs depress glutamatergic transmission (Muly, et al 2007; Grueter and Winder, 2005; Grueter, et al 2006).  Consistent with previous studies, I report that activation of Group III mGluRs with either the general Group III agonist L‐AP4 or the mGluR8‐selective agonist DCPG decreases excitatory transmission in the dorsal BNST.  The change in PPR induced by DCPG, coupled with a significant decrease in sEPSC frequency, suggests that presynaptic mGluR8 is depressing 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transmission by decreasing glutamate release.  As a small effect was also observed on sEPSC amplitude, we cannot exclude the possibility currently that mGluR8 may modulate postsynaptic function as well, though the effects on frequency were much more pronounced.  These data are consistent with the autoreceptor function of mGluR8 seen in other brain regions (Ayala, et al 2008; Valenti, et al 2005; Abitbol, et 
al 2008; Schmid and Fendt, 2006).   I report converging evidence that mGluR8 is the primary mediator of Group III ligand effects on excitatory transmission in the BNST.  First, the mGluR4 allosteric potentiator PHCCC failed to potentiate the effects of the mGluR8‐selective agonist DCPG, suggesting DCPG is acting solely through mGluR8.  Secondly, PHCCC failed to potentiate the effect of the Group III agonist L‐AP4, the orthosteric ligand it is commonly paired with.  Finally, there was no effect of PHCCC or L‐AP4 in slices from mGluR8 KO mice, demonstrating that mGluR8 alone is necessary for the depressive effects of Group III ligands on excitatory transmission in this region.   Of the Group III receptors expressed in the brain, mGluRs 4 and 8 have a similar affinity for glutamate, and L‐AP4 has similar high potency at these two receptors (Schoepp, et al 1999), making mGluR4 the most likely Group III receptor other than mGluR8 to be playing a role in regulating excitatory transmission in the BNST.  The expression of mGluR6 is restricted to retina, ruling out a contribution in the BNST (Nakajima, et al 1993).  It is, however, possible that mGluR7 could have effects on transmission in the BNST, as it is widely expressed in the adult brain.  mGluR7 is unique among mGluRs in that is has a very low affinity for glutamate, and L‐AP4 exhibits very low potency at this receptor (Schoepp, et al 1999).  Due to both the 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low potency of the compound at mGluR7, and also the particularly slow drug on‐rate when L‐AP4 is used in interface settings, it is unlikely that my concentration of 200 
µM L‐AP4, bath applied in an interface chamber, yielded any mGluR7 activation.  Our own previous studies suggest that even in whole‐cell configuration (when slices are submerged, allowing for more efficient drug delivery), near millimolar concentrations of L‐AP4 may be required to activate receptors other than the higher affinity mGluRs 4 and 8 (Grueter, et al 2005).  Therefore, while it is possible that mGluR7 is present in the BNST and able to regulate transmission, it is highly unlikely to be contributing to the drug effects observed in this study.             α1 ARs Can Regulate mGluR8‐Sensitive Inputs I have demonstrated here that mGluR8‐expressing, stress‐sensitive inputs in the dBNST are regulated by α1 ARs.  Previous work has shown that bath application of the α1 AR agonist methoxamine (100 μM) for 20 minutes induces α1 AR‐dependent long‐term depression (α1‐LTD) in the BNST that is modulated by chronic restraint stress (McElligott and Winder, 2008; McElligott, et al 2010).  In this study, the same methoxamine application disrupted subsequent mGluR8‐induced depression of excitatory transmission in the slice, as did both acute and chronic restraint stress.  However, I observed some recovery of mGluR8 function after methoxamine when a high concentration of DCPG (30 μM) was applied.  This indicates that the decreased response to 10 μM DCPG seen after methoxamine likely represents a shift in potency.  One mechanism that could be underlying this shift is a decrease in mGluR8 signaling caused by desensitization or internalization of the receptor.  Importantly, 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in the reverse experiment, DCPG is unable to disrupt α1‐LTD, suggesting that either α1 AR activation is upstream of mGluR8 activation, or α1 ARs regulate transmission at mGluR8‐expressing and non‐expressing inputs.              Stress Can Specifically Regulate mGluR8‐Sensitive Inputs  Currently, the source of the stress‐sensitive, mGluR8‐expressing inputs into the dBNST is unknown.  The BNST receives excitatory inputs from several limbic brain regions and projects to the PVN, a circuitry thought to be activated during anxiety‐related behavior (Walker and Davis, 1997; McElligott, et al 2010).  Both the medial infralimbic cortex (mPFC) and the BLA express mGluR8 mRNA, suggesting these regions could be sending stress‐sensitive processes into the BNST (Allen Mouse Brain Atlas).  Indeed, the BNST is a necessary intermediary in the recruitment of the PVN by the mPFC (Radley, et al 2009).  Local afferent stimulation as performed in the present study likely indiscriminately activates excitatory inputs from many regions; thus, an interesting possibility is that the modest maximal effect of Group III agonists reported here reflects mGluR8 modulation of only a sub‐population of afferents.     Importantly, the regulation of mGluR8 signaling by stress appears to be specific.  I did not observe any obvious alteration in sensitivity to the Group II agonist LY379268 in acutely stressed animals.  Group II receptors are known to be presynaptically expressed in BNST and activate Gi/o signaling, similar to mGluR8 (Muly, et al 2007; Grueter and Winder, 2005).  Their insensitivity to disruption by a single in vivo stressor suggests that mGluR2/3 do not regulate the same set of 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excitatory inputs into the BNST regulated by mGluR8 and α1 ARs.  Further, mGluR5‐mediated LTD is intact after chronic restraint stress, suggesting postsynaptic mGluRs in the BNST may not be engaged during stress exposure (McElligott, et al 2010).  While activation of any known mGluRs in the BNST depresses transmission, this selective disruption of mGluR8 signaling by stress highlights the potential importance of this receptor in regulating specific sets of inputs coming into the BNST.    mGluR8 Function Remains Disrupted After Chronic Stress  Importantly, mGluR8 function is disrupted in α2A AR KO mice, a chronic stress model (Scrhamm, et al 2001), and remains disrupted after chronic stress, conditions under which α1‐LTD is also known to be disrupted in the BNST (McElligott, et al 2010).  The lack of difference between acute and chronic stress effects on mGluR8 function suggests several things.  First, the failure of these synapses to adapt to α1 AR‐mediated loss of mGluR8 function may indicate an important regulatory role for mGluR8 on these inputs.  Likewise, it suggests that these mGluR8‐expressing, stress‐sensitive inputs are bringing information into the BNST that should be overridden in situations of prolonged stress, thus mediating a valuable adaptive response to a stressor.  Lastly, mGluRs throughout the brain play critical roles in gating metaplasticity.  α1 AR activation and subsequent diminished mGluR8 function could be necessary in order to permit activation of other receptors and signaling cascades at these synapses, as part of the brain’s stress response. 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Potential Mechanisms of Stress‐Induced Regulation of mGluR8 In addition to mGluR8, the function of BNST α1 ARs was also attenuated by a single restraint stress, consistent with the idea that α1 ARs in the BNST are activated by in 
vivo stress (McElligott, et al 2010).  A link between α1 ARs, in vivo stress, and Group III mGluRs has previously been made in the PVN (Kuzmiski, et al 2009; Gordon and Bains, 2003).  However, several factors differentiate those studies from the one reported here.  First, the in vivo stressor used in the PVN experiments was hemorrhage‐ a profound, systemic physiological stressor.  Instead, I used either a single, 60‐minute session or a 10‐day chronic protocol of restraint stress, a paradigm shown to increase NE in the BNST and cause activation of α1 ARs (Cecchi, 
et al 2002; McElligott, et al 2010).  Restraint stress is considered to be a more processive stressor than hemorrhage, engaging brain regions such as the BNST that can oppose or allow further activation of stress circuitry via the HPA axis.  Recent work from our laboratory demonstrated that α1‐LTD in the BNST is occluded by chronic restraint stress, suggesting engagement of this form of plasticity during stress (McElligott, et al 2010).  I report here that α1‐LTD in the ex vivo BNST is reduced after a single restraint stress.  By recapitulating the α1 AR‐mediated disruption of mGluR8 signaling with acute and chronic restraint stress, as well as in the chronic stress model of α2A AR KO mice (which exhibit adrenergic disregulation), the current study further supports an occlusion hypothesis, and demonstrates that an acute stressor is sufficient to achieve this occlusion. The studies carried out in the PVN also outline a mechanism by which presynaptic α1 ARs cause desensitization of presynaptic Group III mGluRs, measured by loss of 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L‐AP4 sensitivity.  The location of the α1 ARs disrupting mGluR8 function in the BNST is, as yet, unknown.  Our laboratory has shown previously that post‐synaptic G‐protein signaling is necessary for expression of α1‐LTD, suggesting a postsynaptic locus for α1 ARs (McElligott and Winder, 2008).  One possibility is that postsynaptic α1 ARs are disrupting presynaptic mGluR8 via a retrograde messenger.  However, α1 ARs could exist anywhere at the synapse in BNST, including being present at multiple locations, allowing for other mechanisms of mGluR8 disruption by α1 ARs.  Alternatively, in the hippocampus, presynaptic Group III mGluRs, including mGluR8 specifically, can be inhibited through phosphorylation by PKA (Cai, et al 2001).  Thus, any receptor feeding into the cAMP‐PKA pathway could desensitize mGluR8. Our lab has previously reported that the depressive effects of NE on excitatory transmission in the BNST are time‐dependent (McElligott and Winder, 2008).  A 10‐minute application of NE transiently depresses excitatory transmission in the BNST, while a 20‐minute application induces α1‐LTD, which in turn disinhibits the PVN and allows for HPA axis activation (Cecchi, et al 2002).  I propose that under weak stress, increased excitability in the BNST leads to mGluR8 activation, which in turn depresses excitatory transmission in the region, presumably towards restoring homeostatic norms.  During a single, 60‐minute restraint stress however, BNST levels of NE are elevated for prolonged periods, activating α1 ARs and inducing α1‐LTD.  In prolonging the decrease in glutamatergic transmission, α1‐LTD overrides the signaling mechanisms of mGluR8, perhaps through endocannabinoid signaling.  This LTD is then able to decrease the BNST’s basal inhibition over the PVN, allowing for HPA axis activation in the face of more prolonged stress exposure.  In summary, 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my data indicate a unique role for mGluR8 among Group III mGluRs in the modulation of excitatory transmission in the BNST, and identify this regulation as a target of in vivo stress. 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CHAPTER 5 
 
GENERAL DISCUSSION/CONCLUSIONS  
Implications of mGluR5/ERK/Cocaine Project Findings 
 Though ultimately unsuccessful, this project began to elucidate the mechanisms underlying cocaine‐induced disruption of mGluR5‐LTD in the BNST.  Brad’s finding that DHPG‐LTD after cocaine is rescued by preinjection of MPEP suggested either mGluR5 signaling or the receptor itself was being targeted by cocaine in vivo.  My work suggests that mGluR5 activation is not necessary for cocaine‐induced ERK activation, implying that the disruption of mGluR5 signaling by cocaine‐induced signaling may occur before the level of ERK activation.  These studies also showed no gross difference in surface levels of mGluR5 after chronic cocaine, suggesting that expression of the receptor itself is not a target of cocaine. Taken together, these data suggest that another mediator of mGluR5 signaling may underlie the mechanism by which cocaine disrupts mGluR5‐LTD.  One possibility would be recruitment of distinct signaling cascades via altered homer expression (Patel and Winder, 2010). 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Potential Mechanisms by Which Cocaine Could Regulate mGluR5 Function 
 There are still several potential mechanisms for cocaine‐induced disruption of mGluR5 signaling.  It is likely that cocaine is overriding the intracellular signaling cascades necessary for the induction and/or maintenance of mGluR5‐LTD.  As cocaine is known to increase dopamine levels in the BNST, this occlusion could be occurring downstream of D1 dopamine receptors, which are the receptors thought to be responsible for cocaine‐induced ERK activation in many brain regions (Valjent, 
et al 2004).  If occlusion is occurring, I would expect bath‐applied D1 agonists to disrupt mGluR5‐LTD ex vivo.  Likewise, mGluR5‐LTD should be disrupted in D1 DR knockout mice.   Alternatively, cocaine may be disrupting eCB‐dependent signaling, which has been reported in the striatum (Fourgeaud, et al 2004).  Finally, cocaine is known to induce expression of the immediate‐early gene Homer1a, a dominant negative Homer protein.  Homer1a disrupts the function of long Homer isoforms, which are responsible for coupling Group I mGluRs to internal calcium stores under normal conditions.  After cocaine, Homer1a could effectively halt mGluR5 signal transduction, preventing the release of internal calcium necessary for the expression of mGluR5‐LTD (Grueter, et al 2006).  Or, Homer1a could alter the subcellular localization of mGluR5, causing the receptor to signal through a pathway that may not permit LTD induction.  Future studies with a better pan‐Homer antibody, or subtype‐specific antibodies, would resolve the question of whether cocaine‐induced disruption of mGluR5‐LTD occurs via induction of Homer1a. 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Model of mGluR5 Regulation by Cocaine 
 Glutamatergic transmission is thought to be increased in the BNST after exposure to drugs of abuse.  Therefore, I would hypothesize that this cocaine‐mediated increase in glutamate would recruit the activation of mGluR5.  Once activated, mGluR5 would act to counterbalance this increase in excitatory transmission by activating ERK and inducing LTD.  This in vivo induction of mGluR5‐LTD would thus occlude subsequent attempts to elicit it ex vivo (Figure 19).  Such a model would allow for the receptor to regain its function after the effects of cocaine had subsided.  Indeed, we now know that mGluR5‐LTD is present 10 days after chronic cocaine treatment, and 24 hours after acute cocaine (Grueter et al, 2008).   This hypothesis is further strengthened by the finding that cocaine applied to BNST slices mimics the effect of in vivo cocaine on mGluR5‐LTD, suggesting increased dopamine levels within the BNST could be responsible for increased glutamatergic transmission (Grueter, et al 2008; Kash, Nobis, et al 2008).  Interestingly, stress‐induced ERK activation could occur by a similar mechanism, perhaps explaining why stressed cocaine‐treated mice appeared to exhibit a “ceiling effect” of ERK phosphorylation.  Finally, more direct disruption of mGluR5 signaling via Homer1a induction cannot be ruled out. 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Figure 19. A Hypothesized Model of mGluR5 Regulation by in vivo Cocaine. Under normal conditions, mGluR5 functions normally to regulate glutamatergic transmission. However, cocaine exposure somehow disrupts mGluR5 signaling, possibly preventing ERK1 activation, which is required for mGluR5‐LTD. Alternately, cocaine exposure may increase glutamatergic transmission in the BNST, leading to the activation and subsequent desensitization of mGluR5. Concurrently, cocaine activates D1 dopamine receptors, leading to ERK activation in the BNST and potentially occluding the ERK/MAPK pathway, preventing mGluR5 recruitment of ERK. 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Outstanding Questions, Part I 
 As alluded to above, these data produced more questions than answers.  The mechanism of cocaine‐induced disruption of mGluR5‐LTD is still unknown.  The involvement of Homer1a has not yet been determined.  Interplay between stress‐induced changes and drug‐induced changes have yet to be parsed out, though both may involve increased excitatory transmission in the BNST.  A large outstanding question is what increased glutamatergic signaling and loss of mGluR5 means for the brain regions downstream of the BNST.  As a “middle manager”, the BNST translates incoming limbic information into a functional behavioral or physiological consequence by activating or inactivating downstream effector regions.  Excitability in the BNST is directly related to the excitability of the midbrain DA neurons at the heart of the canonical reward circuitry (Caille, et al 2009).  mGluR5 may therefore play an important role in regulating the excitability of this connection under normal conditions, but become overridden temporarily by drugs of abuse.  Alternately, corticosterone has been shown to be required for acquisition of cocaine reinforcement (for review, see Goeders, 2002).  Given the involvement of the BNST in stress as well as reward circuitry, mGluR5 activation in the BNST by cocaine could be mediating this HPA axis recruitment. Finally, there is the intriguing observation that mGluR5‐LTD is not altered by restraint stress (McElligott, et al 2010), a stimulus which may also increase glutamatergic signaling in the BNST.  This specific disruption of mGluR5 by cocaine 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rather than stress fits with the idea of occlusion mediated by DA signaling.  Interestingly, recent work from our lab suggests NE may similarly increase glutamatergic signaling in the BNST (Nobis, Kash, et al 2011).  An NE‐dependent mechanism could therefore explain the specific disruption we find of mGluR8, but not mGluR2/3 or mGluR5, after stress.   
Relationship Between α1 ARs, mGluR8, and Stress 
 α1 ARs in the BNST are critical regulators of the body’s stress response (Cecchi, et al 2002).  Due to their importance in stress circuitry, it is hard to image that BNST α1 ARs are not mediating the stress‐induced disruption of mGluR8 observed here.   Because stress‐induced disruption did not affect mGluR2/3 function, and because mGluR8 activation did not alter α1 AR activation, mGluR8 signaling appears to be specifically regulated by α1 ARs.  I attempted to address this hypothesis directly in a failed prazosin rescue experiment (data not shown), which yielded a negative result that was impossible to interpret.  The exact mechanism of direct α1 AR‐induced disruption of mGluR8 signaling in the BNST is also unknown, but work in the PVN suggests α1 ARs disrupt presynaptic Group III mGluRs via a PKC‐dependent mechanism (Gordon and Bains, 2003).            
  121 
Model of mGluR8 Regulation by Stress 
 Several studies have suggested that an increase in excitatory transmission in the BNST takes place during and after a stressor.  Recent work from our own laboratory has shown that NE increases glutamatergic transmission in the BNST through a CRF‐dependent mechanism (Nobis, Kash, et al 2011).  I hypothesize that an initial increase in excitatory transmission occurs in the BNST immediately after the onset of stress, as NE is dumped into the BNST via the VNAB.  This increased NE tone translates into an increase in excitability, followed by enhanced glutamatergic transmission via β ARs.  Excitation of the BNST may initially oppose recruitment of the HPA axis, as a safeguard against triggering the body’s stress response unnecessarily.   It is during this early phase that mGluR8 is most likely activated by rising levels of glutamate in the BNST.  mGluR8 activation therefore serves to shut off some of the glutamate sources entering the BNST during a stressor, and will consequently depress transmission at these synapses.  As the duration of the stress progresses, however, α1‐ARs are activated and α1‐LTD is induced throughout the BNST, decreasing excitatory transmission and overriding mGluR8 signaling.  Conversely, it is also possible that α1‐ARs do not override mGluR8 signaling in vivo via a direct mechanism, but instead are activated after mGluR8 has already been desensitized/internalized, providing a second brake opposing excitatory transmission at mGluR8‐expressing inputs. The decrease in overall BNST excitability would then produce a disinhibition of the PVN, allowing for activation of the HPA axis and a systemic stress response (Figure 20).    
  122 
 
Figure 20. A Schematic Model Illustrating the  Regulation of mGluR8 and α1 AR Signaling in the BNST by Stress. Restraint stress induces NE release into the BNST, and may also concurrently increase glutamatergic transmission.  The limbic inputs to the BNST are also sending glutamate into the region, which results in mGluR8 activation.  Once activated, mGluR8 opposes the increasing glutamatergic signaling by decreasing glutamate release from mGluR8‐expressing inputs.  As time passes and the stress persists, NE will induce α1 AR activation in the BNST, inducing α1‐LTD. α1‐LTD will depress excitatory transmission, opposing the stress‐induced increase in glutamatergic signaling.  Finally, based on methoxamine‐induced disruption of mGluR8 signaling, α1 ARs may also directly regulate mGluR8‐expressing synapses. 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Outstanding Questions, Part II  Our data suggest that α1‐ARs are regulating the same stress‐sensitive inputs that express mGluR8.  While occlusion of mGluR8 signaling by α1‐ARs via eCBs or other signaling pathways is possible, during in vivo stress, it is likely that the receptors are activated in series, with mGluR8 being activated first and α1‐AR activation occurring later.  This fits with the time‐dependence of α1‐LTD in the BNST, and with a model of increase glutamatergic tone in the BNST during a stressor.  Future studies should address whether α1‐ARs regulate mGluR8 directly in the slice or during in vivo stress.   Another important future experiment will be to identify the source of the afferents expressing mGluR8 in the BNST.  Because the infralimbic cortex and BLA both express mGluR8 mRNA and send excitatory projections to the BNST, I hypothesize that these inputs would be mGluR8‐positive (Figure 21).  The development of a mouse‐compatible mGluR8 antibody would greatly aide these efforts.  Identifying the origin of these stress‐sensitive inputs will further illuminate the brain circuitry involved in the stress response.   Finally, it would be interesting to see whether different types of stressors (processive versus visceral) would have differing effects on mGluR8 function.  Restraint stress is a fairly processive stressor, presumably activating brain regions like the BNST to decide whether the stressor warrants a physiological stress response.  A more visceral stressor like forced swim test or hypothermia would perhaps not recruit this same set of mGluR8‐inputs into the BNST, leaving mGluR8 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Figure 21. Circuit Diagram Illustrating the Hypothetical Role of mGluR8 in the Brain’s Stress Response Circuitry. Because mGluR8 in the BNST is selectively sensitive to disruption by in vivo stress or α1 ARs, this suggests an important role for mGluR8 in stress signaling.  I hypothesize that mGluR8 is expressed on limbic inputs from the BLA or mPFC, and that these inputs are selectively activated by stress.  Alternately, NE‐induced α1 AR activation in the BNST during stress may directly disrupt mGluR8 function. Overall, the tight regulation of excitatory transmission in the BNST supports the idea of the BNST as a critical relay station for the neural response to a stressor. 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function intact.  It is also unknown how long mGluR8 function remains disrupted after a stressor.  I would predict a fairly rapid return to normal, based on the finding that the mGluR8 signaling pathway showed no adaptation to chronic stress.  
Potential Benefit of This Work to the Study of Human Disease 
 In closing, the data presented in this thesis provide evidence for the importance of mGluRs in modulating excitatory transmission in the BNST during disease states.  Modulatory compounds targeting mGluRs are currently being developed for the treatment of several diseases, including stress/anxiety.  The finding that mGluR8 regulates stress‐sensitive inputs entering the BNST, coupled with its discreet expression pattern, makes mGluR8 an attractive pharmacological target. Further, the finding that α1 ARs cause a shift in DCPG potency ex vivo, rather than a total loss of mGluR8 function, suggests a small population of functional mGluR8 could be present in the BNST after a stressor, and thus able to be targeted by anxiolytic compounds. Already, some studies have shown that the mGluR8‐selective agonist DCPG has anxiolytic effects in mice, though in general the bioavailability of DCPG is thought to be poor (Duvoisin, et al 2010a).  This work also further emphasizes the diversity of important functions managed by the BNST.  Exposure to stress or drugs of abuse can disrupt the function of important mediators of plasticity in this region, possibly through similar mechanisms (a catecholamine‐induced increase in excitatory transmission).  Interestingly, my work also suggests Group II mGluR function in the BNST is stress‐resistant.  Taken together with the cocaine‐specific 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disruption of mGluR5 function, this thesis further delineates a role for each of the 3 mGluR subgroups in regulating excitatory transmission in the BNST.  It is amazing how a class of similar receptors, with comparable functions, within the same brain region, could individually tune the BNST to the current external environment via its own set of synapses. 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APPENDIX A  
The Effect of DCPG may be Altered by Acute and Chronic Cocaine 
 A few studies have reported changes in mGluR8 mRNA or protein levels following exposure to psychostimulants.  Acute cocaine administration causes a decrease in mGluR8 protein in the rat striatum that reverses after 6 hours (Zhang, et al 2009).  Conversely, mGluR8 mRNA is upregulated in the rat forebrain after acute amphetamine (Parelkar and Wang, 2008).  I hypothesized that mGluR8 function in the BNST might be disrupted by acute or chronic cocaine.  However, my findings were mixed over several cohorts of animals.  In some cohorts, the effect of DCPG appeared to be blunted in slices from cocaine‐treated animals.  However, in other cohorts, the effect of DCPG was also decreased in saline‐treated mice (Figure 22).  Stressful housing conditions were a potential confounding factor, as we now know 
in vivo stress can robustly disrupt mGluR8 function in the BNST.  Ultimately, these studies caused us to alter how my animals were housed, and shifted my focus from drug‐induced changes in mGluR8 function to stress. 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Figure 22. The Effect of DCPG May be Altered in Slices From Cocaine‐Treated Mice. (a) The effect of a single injection of cocaine or saline on DCPG sensitivity. (n = 7 for cocaine, red circles; n = 3 for saline, black circles). (b) The effect of chronic cocaine or saline on DCPG sensitivity. (n = 7 for cocaine, red circles; n = 8 for saline, black circles). 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APPENDIX B 
 
DCPG May Facilitate Single­Train LTP  In the PVN, α1 ARs activated by stress inhibit presynaptic Group III mGluRs, which maintain a low level of glutamate release at these synapses under basal conditions (Gordon and Bains, 2003, Kuzmiski, et al 2009).  This metaplastic disinhibition is permissive for a form of LTP, which can be induced via a subthreshold stimulation protocol that does not induce LTP under basal conditions.  I hypothesized that mGluR8 activation (and subsequent inactivation/desensitization) in the BNST could be permissive for a similar form of subthreshold LTP in this region.  Under normal conditions, LTP cannot be induced in the BNST using a single train 100 Hz protocol.  However, application of DCPG for 20 minutes prior to the tetanus appeared to facilitate an LTP‐like plasticity (Figure 23).  Though preliminary, this data could suggest basal activation of excitatory transmission in the BNST by mGluR8.  If this LTP‐like plasticity is also present after stress, this would further support the idea of stress‐induced metaplasticity, such as that seen in the PVN. 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Figure 23. DCPG May Facilitate Sub‐Threshold LTP in the BNST. 10 μM DCPG prior to a single tetanus appears to increase the size of the tetanus‐induced plastcitiy. (DCPG control, n = 8, red circles; single train LTP, n = 4, green triangles; DCPG + single train LTP, n = 3, black squares). 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APPENDIX C  
Novel mGluR4/8 Potentiator AZ12216052 Depresses Transmission in BNST 
 In my initial attempts to characterize the effects of Group III mGluRs on excitatory transmission in the BNST, I utilized a compound that positively regulates mGluR8, AZ12216052 (Duvoisin, et al 2010).  Slices were bathed in 10 µM AZ12216052 for 30 minutes, followed by a 20‐minute co‐application of AZ12216052 and 200 µM L‐AP4 (16.7 ± 2.8 peak average percent depression vs. baseline, p ≤ 0.0001, student’s t‐test; Figure 24A).   A small but significant effect of AZ12216052 alone on excitatory transmission was observed (Figure 24A,C).  The subsequent effect of L‐AP4 in the presence of AZ12216052 was not significantly different from that of L‐AP4 alone (16.7 ± 2.8 compared to 13.1 ± 2.7 peak average percent depression of L‐AP4 alone in vehicle, Figure 24C).  To determine whether the effects of AZ12216052 were mediated by mGluR8, these experiments were repeated using slices from mGluR8 knockout mice (Figure 24B).  Neither AZ12216052 nor L‐AP4 had any effect in mice lacking mGluR8, demonstrating that the effects of these compounds require mGluR8 (AZ effect in KO: 0.3 ± 2.3 peak average percent depression vs. 5.9 ± 1.7 in WT, p < 0.05, student’s t‐test; Figure 24D). Taken together, these data further confirmed the primary role of mGluR8 in mediating the effects of Group III ligands on transmission in the BNST. 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Figure 24. The Effect of the mGluR8 Potentiator AZ12216052 on Transmission in BNST is Mediated by mGluR8. (a) 10 μM AZ12216052 depresses excitatory transmission in BNST (p ≤ 0.0001 versus baseline, student’s t‐test, n = 7). (b) The effect of AZ12216052 + L‐AP4 is absent in slices from mGluR8 knockout mice (n = 5). (c) Analysis of peak effect of average percent depression induced by AZ12216052, L‐AP4, or in combination, on WT and mGluR8 knockout mouse slices (#p ≤ 0.005 compared to WT, *p ≤ 0.01 compared to baseline, student’s t‐test) . (d) Peak average percent depression of 10 μM AZ12216052 alone in WT and mGluR8 knockout mouse slices. 10 μM AZ12216052 causes a small but significant depression of transmission on its own that is absent in slices from mGluR8 knockout mice (*p ≤ 0.01 compared to baseline, #p = 0.05, WT vs. KO, student’s t‐test, n = 5‐7). 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These studies were the first use of AZ12216052 on brain slices.  Because the effect of AZ + L‐AP4 was not significantly different from the peak effect of L‐AP4 alone, this suggests AZ is at best a weak potentiator.  Interestingly, I observed a small but significant depression in transmission with AZ12216052 alone.  This depression could be explained several different ways.  It is possible that AZ12216052 has intrinsic agonist activity at mGluR8, such that it is able to activate the receptor on its own, without an orthosteric ligand such as L‐AP4 being present.  Alternatively, it is possible that mGluR8 is basally activated by glutamate in the slices.  If this second scenario were occurring, then addition of a potentiator such as AZ12216052 would increase this baseline mGluR8 activation, causing a depression in the presence of AZ12216052 alone.  In either case, the depression caused by AZ12216052 is absent in mGluR8 knockout mice, demonstrating a requirement for mGluR8 in these effects.  Overall, AZ12216052 was a poor compound for slice work due to its solubility issues, very mild potentiator effects, and lack of selectivity between mGluR4/8. 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